Transdermal fentanyl was released in Germany in 1995. From October 1996 to February
1998 transdermal treatment was documented for 1005 patients (506 men and 499 women …

The transdermal therapeutic system with fentanyl was released in Germany in 1995. Before
and after the release several clinical trials were performed in our pain management unit and …

Transdermal fentanyl offers the advantage of providing continuous administration of a potent
opioid in the absence of needles and expensive drug-infusion pumps for the treatment of …

The long-term therapy of 51 patients using transdermal fentanyl was evaluated. The
transdermal therapy was performed for 158 days (range, 15–855 days). The need for …

In this study, 6 patients with pain from advanced cancer were enrolled in a multicenter, open-
label seeding trial of transdermal fentanyl. Following equianalgesic dose conversion …

Transdermal (TTS) fentanyl therapy has emerged as an effective alternative to the use of
oral opioids for the control of pain in certain cancer patients. These patients are those with …

We observed 73 cancer patients receiving transdermal fentanyl for 1–29 (mean 5.5) months
immediately after participation in a randomized clinical trial. Of these, 32 received fentanyl …

A multicenter study was conducted to determine the patient and physician acceptability of
transdermal fentanyl in the management of cancer-related pain. In this study, 10 cancer …

To treat cancer pain, physicians often decide to jump directly from step 1 of the World Health
Organization (WHO) analgesic ladder to step 3. The use of transdermal fentanyl in patients …

We performed an open-label pilot study to define analgesic efficacy, acceptability, and
toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our …